Dermacyte Oxygen Concentrate
Oxygen Biotherapeutics, Inc. today announced that the company has begun distribution for its newly formulated Dermacyte Oxygen Concentrate for the beauty and skin care market. The over-the-counter product is a scientifically designed perfluorocarbon concentrate to enhance oxygen delivery to skin. As of later this week, retail orders also can be placed on the Dermacyte secure website at www.BuyDermacyte.com.
“Inventory of Dermacyte sold out quickly last fall when it was originally introduced in a market test designed to gauge customer interest and response,” said Chris Stern, company chairman and CEO. “The feedback we received from customers was quite positive. We’ve improved the Dermacyte concentrate to be smoother and more effective. Therefore, we believe that our new cosmetic line has the potential to be a significant financial contributor to our company.”
Dermacyte Oxygen Concentrate is the first product in a broad and diverse cosmetic line currently under development. It uses the company’s patented Oxycyte technology, an oxygen carrier scientifically designed to enhance oxygen delivery to tissues such as skin. Some potential benefits of increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles and dryness.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine. The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.
See Also:
If you enjoyed this post, please consider leaving a comment, subscribe to the feed and get future articles delivered to your feed reader or follow us on Twitter.
Comments
[…] Oxygen Biotherapeutics, Inc. today announced that results from an 8-week cosmetic study showed that the topical application of DERMACYTE Oxygen Concentrate, an oxygen-rich skin care lotion, appears to improve the appearance of fine lines and the perception of skin appearance. The study was conducted by Steven H. Dayan, MD, of DeNova Research in Chicago with funding provided by Oxygen Biotherapeutics. […]
[…] Dermacyte Oxygen Concentrate […]